Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cellular concentrations of Protein Kinase D1 in HEK293T and INS-1 cells

ABSTRACT: Protein kinase D1 (PRKD1, also referred to as PKD1), has been proposed to undergo concentration dependent dimerization in vitro. To test whether the cellular concentration of PKD1 is in the range of the dissociation constant obtained, the expression level of PKD1 was investigated by PRM. To this end, an equimolar mixture of pure, recombinant protein comprising the PKD N-terminus (residues 48-198) and C-terminus (residues 395-892) was used to spike the cell lysates of human HEK293T cells or the rat cell line INS-1. In the latter case, only peptides that are identical between the human and rat PKD1 protein were used to estimate the cellular expression level of PKD1.

INSTRUMENT(S): Orbitrap Fusion Lumos, Q Exactive HF

ORGANISM(S): Rattus Norvegicus (rat) Homo Sapiens (human)

SUBMITTER: Markus Hartl

LAB HEAD: Thomas A. Leonard

PROVIDER: PXD013232 | Pride | 2019-08-19

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

A ubiquitin-like domain controls protein kinase D dimerization and activation by trans-autophosphorylation.

Elsner Daniel J DJ Siess Katharina M KM Gossenreiter Thomas T Hartl Markus M Leonard Thomas A TA

The Journal of biological chemistry 20190812 39

Protein kinase D (PKD) is an essential Ser/Thr kinase in animals and controls a variety of diverse cellular functions, including vesicle trafficking and mitogenesis. PKD is activated by recruitment to membranes containing the lipid second messenger diacylglycerol (DAG) and subsequent phosphorylation of its activation loop. Here, we report the crystal structure of the PKD N terminus at 2.2 Å resolution containing a previously unannotated ubiquitin-like domain (ULD), which serves as a dimerization ...[more]

PMID: 31406020

Similar Datasets

Polycystic Kidney Disease Progression Expression Analysis

Project description:Polycystic Kidney Disease (PKD) is a genetic disease of the kidney characterized by the gradual replacement of normal kidney parenchyma by fluid-filled cysts and fibrotic tissue. Autosomal Dominant Polycystic Kidney Disease (ADPKD) is caused by mutations in the PKD1 or PKD2 gene. Here we present an RNASeq experiment designed to investigate the effect of a kidney specific and Tamoxifen inducible knockout of the Pkd1 gene in mice. The Pkd1cko mice were harvested at different time points 2-weeks, 3-weeks, 5-weeks, 10.5-weeks, 11-weeks and 15-weeks after gene inactivation.

2019-12-24 | E-MTAB-8086 | biostudies-arrayexpress

RNA seq of fluid shear stress treated mouse Pkd1-/- renal epithelial cells

Project description:Pkd1-/- renal epithelial cells are exposed to mechanical forces due to flow-induced shear stress within the nephrons. We applied RNA sequencing to get a comprehensive overview of fluid-shear regulated genes and pathways in the immortalized Pkd1-/- renal proximal tubular epithelial cell line. Cells were exposed to laminar fluid shear stress (1.9 dyn/cm2) in a cone-plate device and compared to static controls.

2019-03-01 | E-MTAB-6641 | biostudies-arrayexpress

An ‘omics approach to unraveling the paradoxical effect of diet on perfluorooctanesulfonic acid (PFOS) and perfluorononanoic acid (PFNA) induced non-alcoholic fatty liver disease (NAFLD)

Project description:Perfluoroalkyl substances (PFASs) are a family of toxicants universally detected in human serum and known to cause dyslipidemia in animals and humans. Non-alcoholic fatty liver disease (NAFLD) is most prevalent form of liver disease in the United States and has been rising in global prevalence over recent years. This study explored diet-PFAS interactions and their potential role in the increasing global incidence of NAFLD. Male C57BL/6 mice were fed with either a low-fat diet (10% kcal from fat) or a moderately high fat diet (45% kcal from fat) with or without perfluorooctanesulfonic acid (PFOS) or perfluorononanoic acid (PFNA) at a low dose of 0.0003% w/w in feed for 12 weeks. Livers were excised for histology and quantification of PFASs and lipids. Proteomics and transcriptomics were utilized to conduct mechanistic pathway exploration. In a high fat diet, PFOS and PFNA protected against the onset of hepatic lipid accumulation and inflammatory progression. Genes and proteins related to lipid metabolism, synthesis, transport, and storage were modulated by PFAS exposure and further impacted by the presence of dietary fat. When combined with a high fat diet, low dose PFOS and PFNA are protective against the onset of NAFLD suggesting that dietary fat impacts the behavior of PFASs in vivo. Furthermore, both dietary fat content and the chemical functional head group exerted significant influence on tissue partitioning and the resulting hepatic biochemical signature.

2021-02-18 | PXD015977 | Pride

First evidence that a protein coded by a short ORF, not by the annotated CDS is the main gene product

Project description:Proteogenomics and ribosome profiling concurrently show that genes may code for both a large and one or more small proteins translated from annotated coding sequences (CDSs) and unannotated alternative open reading frames (named alternative ORFs or altORFs), respectively, but the stoichiometry between large and small proteins translated from the same gene is unknown. \textit{MIEF1}, a gene recently identified as a dual-coding gene, harbours a CDS and a newly annotated and actively translated altORF located in the 5’UTR . Here, we use absolute quantification with stable isotope-labeled peptides and parallel reaction monitoring to determine levels of both proteins in two human cells lines and in human colon. We report that the main \textit{MIEF1} translational product is not the canonical 463 amino acid MiD51 protein but the small 70 amino acid alternative MiD51 protein (altMiD51). These results demonstrate the inadequacy of the single CDS concept and provide a strong argument for modernizing functional annotations of genes.

2018-11-21 | PXD008147 | Pride

Analysis of PKD1 autophosphorylation in vitro and confirmation of stoichiometric S742 phosphorylation of a recombinant PRKD1 kinase domain

Project description:Protein kinase D1 (PRKD1, also referred to as PKD1), has been proposed to undergo autophosphorylation on serine 742 and potentially also on serine 738 in the activation loop of its kinase domain. We used recombinant PKD1 kinase domain to test whether PKD1 is indeed able to undergo autophosphorylation of its kinase domain and how many sites could be phosphorylated. In order to obtain fully phosphorylated PKD1 kinase domain we adapted our autophosphorylation protocol to obtain monophosphorylated PKD1 kinase domain and determined the phosphorylation site by ArgC digest and phosphopeptide mapping.

2019-08-19 | PXD013216 | Pride

Identification of biomarkers for PKD1 using urinary exosomes

Project description:Autosomal dominant polycystic kidney disease (ADPKD) is a common cause of ESRD. Affected individuals inherit a defective copy of either the PKD1 or PKD2 gene, encoding the proteins polycystin?1 (PC1) or polycystin?2 (PC2) respectively. PC1 and PC2 are secreted on urinary exosome?like vesicles (ELVs) (100nm diameter vesicles), where PC1 is present in a cleaved form and may be complexed with PC2. Label free quantitative proteomic studies of urine ELVs in an initial discovery cohort (13 PKD1 and 18 Normals), revealed that of 2008 ELV proteins, nine (0.32%) showed a statistically significant difference between PKD1 and normals at a p<0.025. PC1 was reduced to 54% of the normal level (p<0.02) and PC2 reduced to 53% (p<0.001). TMEM2, a protein with homology to fibrocystin, the product of the polycystic hepatic and kidney disease (PKHD1) gene, is increased 2.1 fold (p<0.025). The PC1/TMEM2 ratio correlated inversely with height adjusted total kidney volume (HtTKV) in the discovery cohort and the ratio of PC1/TMEM2 or PC2/TMEM2 could be used to distinguish PKD1 from normals in a confirmation cohort. In summary, this study suggests that a test based on the urine exosomal PC1/TMEM2 or PC2/TMEM2 ratio may have utility in the diagnosis and perhaps monitoring of PKD1.

2014-12-02 | PXD001075 | Pride

Integrating serum protein electrophoresis with mass spectrometry, a new workflow for M-protein detection and quantification

Project description:Serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) are standard tools for multiple myeloma (MM) routine diagnostics. M-protein is a biomarker for MM that can be quantified with SPE and characterized with IFE. We have investigated combining SPE/IFE with targeted mass spectrometry (MS) to detect and quantify the M-protein. SPE-MS assay offers the possibility to detect M-protein with higher sensitivity than SPE/IFE, which could lead to better analysis of minimal residual disease in clinical laboratories. In addition, analysis of archived SPE gels could be used for retrospective MM studies. We have investigated two different approaches of measuring M-protein and therapeutic monoclonal antibodies (t-mAbs) from SPE/IFE gels. After extracting proteotypic peptides from the gel, they can be quantified using stable isotope labeled (SIL) peptides and measured by Orbitrap mass spectrometry. Alternatively, extracted peptides can be labeled with tandem mass tags (TMT). Both approaches are not hampered by the presence of t-mAbs. Using SIL peptides, limit of detection of the M-protein is approximately 100-fold better than with routine SPE/IFE. Using TMT labeling, M-protein can be measured and compared in different samples from the same patient. We have successfully measured M-protein proteotypic peptides extracted from the SPE/IFE gels utilizing SIL peptides and TMT.

2020-01-07 | PXD016325 | Pride

Development of a parallel reaction monitoring-MS method to quantify IGF proteins in dogs: application to a canine case study of NICTH syndrome

Project description:Non–islet-cell tumor hypoglycemia (NICTH) is a rare paraneoplastic phenomenon seen in both dogs and humans. NICTH syndrome is derived from incompletely processed forms of insulin-like growth factor–II (IGF–II) by tumors, commonly named as big IGF–II. In the present study, a previously developed targeted PRM MS-based method for cats have been optimized and applied to simultaneously quantify the levels of IGF–I, IGF–II, and IGFBP–3, and for the first time, the levels of big IGF–II in dogs. This method allows the absolute quantification of these proteins using a mixture of QPrEST™ proteins previously designed for humans, reducing the variations due to the methodology, and the amount of serum needed for the analysis.

2018-11-04 | PXD009277 | Pride

Comparison of targeted mass spectrometry techniques with an immunoassay: a case study for HSP90 alpha, part 1

Project description:We developed 2D-LC-MS/MS-based SRM and PRM assays to measure HSP90 alpha in serum and compared the results to a commercially available immunoassay (ELISA). Serum samples were trypsin-digested and fractionated by SCX chromatography prior to SRM and PRM measurements. PRM data obtained by high-resolution mass spectrometry correlated better with ELISA measurements than SRM data measured on a triple quadrupole mass spectrometer. While all three methods (SRM, PRM, ELISA) were able to quantify HSP90 alpha in serum at the ng/mL level, the use of PRM on a high-resolution mass spectrometer reduced variation. To rule out that the observed differences in SRM and PRM are due to different mass spectrometry systems, the SCX fractions were measured on the same high-resolution instrument (Orbitrap) in the ion trap mode (IT-PRM); such measurements showed that intense co-eluting signals were present in the SRM method, but these interfering peaks were eliminated in the high-resolution PRM mode. Thus, this report shows that it is possible to measure ng/mL levels of HSP90 alpha in a reproducible, selective and sensitive way using PRM. This opens up the possibility to quantify low levels of multiple proteins in complex samples based on a fractionation strategy on tryptic peptides followed by SRM and PRM.

2018-07-05 | PXD006618 | Pride

Protein kinase D1 deletion in adipocytes enhances energy dissipation and protects against adiposity

Project description:DAG-activated Pkd1 promotes triglyceride accumulation in adipocytes; Pkd1 promotes lipogenesis and suppresses mitochondrial function in adipocytes in an AMPK-dependent manner; Pkd1 suppresses expression of genes characteristic for beige adipocytes; Deletion of Pkd1 in adipocytes protects mice from diet-induced obesity, T2D and liver steatosis.

2018-09-20 | GSE104797 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data